vimarsana.com

Seven abstracts to be presented demonstrating treatment effects of Bylvay® in two cholestatic liver diseases, progressive familial intrahepatic cholestasis and Alagille syndrome Data to be... | June 12, 2023

Related Keywords

Paris ,France General ,France ,Austria ,Shanghai ,China ,Vienna ,Wien ,United States ,Netherlands ,Italy ,Canada ,Cambridge ,Cambridgeshire ,United Kingdom ,Belgium ,San Sebastian ,Pais Vasco ,Spain ,Toronto ,Ontario ,Saclay ,Germany ,Groningen ,American ,America ,Marwan Sleiman ,Franciscoj Caballero Camino ,Henkjan Verkade ,Amy Wolf ,Asia Pacific ,Bettina Hansen ,Peter Serafini ,Ahmed Ghallab ,Ekkehard Sturm ,Ipsen Euronext ,Ioana Piscociu ,Emmanuel Gonzal ,Anna Gibbins ,Howard Mayer ,Georg Friedrich Vogel ,Department Of Paediatrics ,Global Medical Affairs ,University Of The Basque Country ,University Of Innsbruck ,Leibniz Research Centre For Working Environment ,Department Of Liver ,Centre For Liver ,University Of Groningen ,Institute Of Cell Biology ,University Of Toronto ,Head Of Corporate Brand Strategy Communications ,Head Of Research ,Global Head Of Franchise Communications ,Donostia University Hospital ,Department Of Epidemiology Biostatistics ,Toronto Centre For Liver Disease ,Technical University Dortmund ,European Association For The Trial Of Liver ,Department Of Toxicology ,University Of Birmingham ,University Children Hospital ,Gastrointestinal Research ,Beatrix Children Hospital University Medical Centre Groningen ,Biodonostia Health Research Institute ,University Health Network ,European Association ,Itch Numeric Rating Scale ,Short Form ,Executive Vice President ,Biliary Diversion ,Toronto Centre ,Liver Disease ,Beatrix Children ,University Medical Centre Groningen ,Palak Trivedi ,National Institute ,Paediatric Gastroenterology ,University Children ,Medical University ,Cell Biology ,Director Global Market Access ,Global Medical Affairs Director ,Leibniz Research Centre ,Working Environment ,Human Factors ,Gastrointestinal Diseases ,Basque Country ,North America ,Middle East ,Reported Outcome ,Institutional Review Board Approved ,Breakthrough Therapy ,Rare Disease ,Sponsored Level ,American Depositary Receipt ,Franchise Communications ,Corporate Brand Strategy ,

© 2024 Vimarsana

vimarsana.com © 2020. All Rights Reserved.